ADC terminates Phase II trial for lymphoma therapy
The Phase II trial for Zynlonta and Rituxan in DLBCL patients was discontinued after US FDA placed a partial clinical hold on the trial.
The Phase II trial for Zynlonta and Rituxan in DLBCL patients was discontinued after US FDA placed a partial clinical hold on the trial.
What's Your Reaction?
